As a pharma company looks to make the transition from a traditional pre-filled syringe (PFS) to an auto-injector, both its device partner and its manufacturing partner must bring their own set of expertise to the 3-way partnership. It's imperative that the three teams work together to meet product, device, quality, manufacturing, and packaging requirements. When experienced partners understand lifecycle management and anticipate equipment and process needs, the product can be transitioned from PFS to auto-injector more quickly.
In this webinar, Ypsomed and Catalent Biologics will share:
- How product characteristics and formulation determine the type of auto-injector best suited for your product
- How the chosen auto-injector affects manufacturing and packaging of the finished product
- What quality considerations are necessary as a product transitions to auto-injector
- How the above coupled with integrated PFS manufacturing and auto-injector assembly can create an accelerated timeline to market